Payment overview · 2025
General Payments
$486.98
26 reported records · 14 companies
Healthcare provider profile · identity verified
Imran Plumb, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DURANT, OK · NPI 1275827305
Verified facts
What the public records show
CMS Open Payments records show Imran Plumb, M.D. received $486.98 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.63 | 22.7% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $59.60 | 12.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.78 | 11.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.36 | 9.5% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $35.40 | 7.3% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.54 | 6.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.33 | 6.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.24 | 4.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.95 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.55 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.77 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.40 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.35 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.98 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.63 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $59.60 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 187 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
187 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
221 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 734 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 152 |
| Gabapentin | Gabapentin | 517 | 107 |
| Omeprazole | Omeprazole | 490 | 140 |
| Potassium Chloride | Potassium Chloride | 424 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 107 |
| Montelukast Sodium | Montelukast Sodium | 392 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 105 |
| Lisinopril | Lisinopril | 351 | 95 |
| Furosemide | Furosemide | 350 | 98 |
| Losartan Potassium | Losartan Potassium | 317 | 94 |
| Trazodone Hcl | Trazodone Hcl | 316 | 87 |
| Alprazolam | Alprazolam | 279 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 277 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 96 |
| Metformin Hcl | Metformin Hcl | 270 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 67 |
| Sertraline Hcl | Sertraline Hcl | 262 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 57 |
| Eliquis | Apixaban | 221 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 202 | 51 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 201 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 191 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 187 | 48 |
| Tramadol Hcl | Tramadol Hcl | 182 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 32 |
| Meloxicam | Meloxicam | 169 | 44 |
| Pregabalin | Pregabalin | 169 | 34 |
| Ondansetron Odt | Ondansetron | 168 | 59 |
| Ibuprofen | Ibuprofen | 164 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 162 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 156 | 51 |
| Mirtazapine | Mirtazapine | 154 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 151 | 58 |
| Carvedilol | Carvedilol | 134 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 29 |
| Methylprednisolone | Methylprednisolone | 131 | 96 |
| Allopurinol | Allopurinol | 127 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 26 |
| Ozempic | Semaglutide | 121 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 117 | 30 |
| Memantine Hcl | Memantine Hcl | 113 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 37 |
| Azithromycin | Azithromycin | 110 | 91 |
| Ezetimibe | Ezetimibe | 110 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 20 |
| Baclofen | Baclofen | 106 | 24 |
| Simvastatin | Simvastatin | 105 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 46 |
| Temazepam | Temazepam | 90 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 17 |
| Jardiance | Empagliflozin | 88 | 18 |
| Spironolactone | Spironolactone | 88 | 34 |
| Clonazepam | Clonazepam | 85 | 15 |
| Finasteride | Finasteride | 85 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 31 |
| Mounjaro | Tirzepatide | 80 | 21 |
| Glipizide | Glipizide | 79 | 20 |
| Movantik | Naloxegol Oxalate | 79 | 17 |
| Donepezil Hcl | Donepezil Hcl | 78 | 17 |
| Buspirone Hcl | Buspirone Hcl | 77 | 17 |
| Nystatin | Nystatin | 75 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 75 | 17 |
| Linzess | Linaclotide | 74 | 16 |
| Levofloxacin | Levofloxacin | 73 | 57 |
| Topiramate | Topiramate | 73 | 19 |
| Risperidone | Risperidone | 70 | 11 |
| Fluconazole | Fluconazole | 69 | 47 |
| Sucralfate | Sucralfate | 68 | 22 |
| Famotidine | Famotidine | 66 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 41 |
| Alendronate Sodium | Alendronate Sodium | 63 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Estradiol | Estradiol | 61 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 16 |
| Levetiracetam | Levetiracetam | 59 | 12 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 48 |
| Diazepam | Diazepam | 57 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 48 |
| Metformin Hcl Er | Metformin Hcl | 56 | 19 |
| Celecoxib | Celecoxib | 55 | 17 |
| Farxiga | Dapagliflozin Propanediol | 55 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 13 |
| Lactulose | Lactulose | 53 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Myrbetriq | Mirabegron | 52 | 14 |
| Xarelto | Rivaroxaban | 51 | 11 |
| Promethazine Hcl | Promethazine Hcl | 46 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 15 |
| Januvia | Sitagliptin Phosphate | 41 | 13 |
| Meropenem | Meropenem | 41 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Nitroglycerin | Nitroglycerin | 39 | 28 |
| Valacyclovir | Valacyclovir Hcl | 37 | 11 |
| Clozapine | Clozapine | 36 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 11 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | 16 |
| Lidocaine | Lidocaine | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | 11 |
| Acyclovir | Acyclovir | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Constulose | Lactulose | 29 | 19 |
| Zafirlukast | Zafirlukast | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Atenolol | Atenolol | 27 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Methocarbamol | Methocarbamol | 25 | 12 |
| Metolazone | Metolazone | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Repaglinide | Repaglinide | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Klayesta | Nystatin | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Riluzole | Riluzole | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.98 · 26 records | Novo Nordisk Inc | AREXVY, ARISTADA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, GEMTESA, INCEPTIV, JOURNAVX, LYBALVI, MAVYRET, NURTEC ODT, OTEZLA, Ozempic, PROCLAIM, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error